Pharmaceutical Industry and Drugs

Johnson & Johnson Hit With Record Talc-Ovarian Cancer Verdict of $417 Million

Johnson & Johnson Hit With Record Talc-Ovarian Cancer Verdict of $417 Million

A Los Angeles jury today ordered Johnson & Johnson to pay damages of $417 million to a 62-year-old woman who blamed her ovarian cancer on years of using the company’s baby powder for feminine hygiene. It was the first California trial in the mushrooming legal battle over links between genital use of talc and ovarian…

Scientists Urge Tighter Scrutiny of Germ-Fighting Chemicals FairWarining Reports

Scientists Urge Tighter Scrutiny of Germ-Fighting Chemicals

More than 200 scientists and public health advocates are urging regulators to take a closer look at the potential dangers of antimicrobial chemicals including triclosan, an additive that has been banned from hand soaps but remains an active ingredient in products ranging from building materials to Colgate’s Total toothpaste. The call for better labeling and…


How to Stop Drug Price Gouging

One of Donald Trump’s few universally welcomed campaign promises was to do something about the prices of pharmaceutical drugs. Most Americans recognize that prices are too high, and are bothered by the rise of pharmaceutical price gouging. But what few people realize is that the president already has the power to do something about drug…

Johnson & Johnson Wins Its First Talc-Ovarian Cancer Case FairWarining Reports

Johnson & Johnson Wins Its First Talc-Ovarian Cancer Case

Editor's note: See update at bottom of story.

Breaking a string of lopsided courtroom defeats, Johnson & Johnson scored a legal victory Friday when a St. Louis jury rejected the claim of an ovarian cancer victim that her use of talc powders for feminine hygiene caused the disease. The defense verdict in St. Louis Circuit Court followed three plaintiffs’ victories last year with…

Brain Boosters a Gold Mine for Supplements Industry But Benefits Are Hotly Disputed FairWarining Investigates

Brain Boosters a Gold Mine for Supplements Industry But Benefits Are Hotly Disputed

A few years ago, motivated by a family history of dementia, Bea Pena-Reames began using a dietary supplement that promised improved memory and brain health. It was advertised as safe and effective – but that was not her experience. “I’m typically a joyful person, but I couldn’t shake this depression and intense sense of sadness,”…

Swarms of Drug Industry Lobbyists and Campaign Cash Stymie Bid to Restrain Medicare Prescription Costs FairWarining Investigates

Swarms of Drug Industry Lobbyists and Campaign Cash Stymie Bid to Restrain Medicare Prescription Costs

See the editor’s note at the bottom of this story. When the Republican-controlled Congress approved a landmark program in 2003 to help seniors buy prescription drugs, it slapped on an unusual restriction: The federal government was barred from negotiating cheaper prices for those medicines. Instead, the job of holding down costs was outsourced to the…

Drug Companies Pony Up in Illegal Marketing Cases, But Critics Wonder if Penalties are Enough FairWarining Reports

Drug Companies Pony Up in Illegal Marketing Cases, But Critics Wonder if Penalties are Enough

If you make truck deliveries in the overcrowded downtown streets of a big city, parking tickets might simply be a cost of doing business. For top drug companies, critics say, there’s an equivalent expense — the billions of dollars paid out to settle criminal and civil charges of illegal marketing practices, Medicaid overcharges and kickbacks….

Another Big Defeat for Johnson & Johnson in Talc-Ovarian Cancer Case FairWarining Reports

Another Big Defeat for Johnson & Johnson in Talc-Ovarian Cancer Case

Johnson & Johnson suffered a second straight legal defeat in defense of its signature talc products on Monday when it was ordered to pay $55 million in damages to a woman who blamed her ovarian cancer on the use of Johnson’s Baby Powder for feminine hygiene. After about 10 hours of deliberations, a state court…

Johnson & Johnson Dealt $72 Million Courtroom Loss in Talc-Ovarian Cancer Case FairWarining Reports

Johnson & Johnson Dealt $72 Million Courtroom Loss in Talc-Ovarian Cancer Case

Johnson & Johnson has suffered a major courtroom defeat in the first in a wave of lawsuits claiming that talc products marketed by the company for feminine hygiene use caused ovarian cancer. A jury in St. Louis late Monday night ordered the health care products giant to pay $72 million in compensatory and punitive damages…